Antibody-drug conjugates (ADCs) continue to emerge as one of the fastest-growing biologics segments globally. Increased oncology pipeline activity and growing regulatory approvals are driving strong demand for specialized ADC development and manufacturing capabilities.
This has triggered significant investment across Europe in:
- High-potent API manufacturing
- Conjugation capabilities
- Sterile fill-finish
- Containment facilities
- Specialized analytical services
Several European CDMOs have announced facility expansions and investments to capture increasing ADC outsourcing demand.
Key Drivers:
- Rapid growth in oncology biologics pipelines
- Increased ADC approvals globally
- High technical barriers limiting supplier availability
- Demand for integrated drug substance and drug product services
- Limited commercial-scale ADC manufacturing capacity
CDMOs Positioned for ADC Outsourcing Growth:
- Lonza
- BSP Pharmaceuticals
- Axplora
- Sterling Pharma Solutions
- Piramal Pharma Solutions
- Fareva
- CARBOGEN AMCIS
- Cerbios-Pharma
- CordenPharma
- Recipharm
What This Means for Sponsors
Pharma companies are increasingly prioritizing CDMOs with integrated ADC capabilities to reduce tech transfer complexity and accelerate clinical timelines. Demand is expected to continue outpacing available specialized manufacturing capacity.
